Scoop: Gilead outlines plans to muscle up its manufacturing arm after Immunomedics layoffs

Gilead has had a no good, very bad week thus far. On Monday, the company revealed Phase III data for its prized $21 billion Immunomedics drug that fell flat on Wall Street, and then Tuesday, reports first emerged that Gilead is planning to lay off 114 staffers from Immunomedics’...

Click to view original post